Welcome to our dedicated page for Biocardia SEC filings (Ticker: BCDAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Biocardia's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Biocardia's regulatory disclosures and financial reporting.
BioCardia (NASDAQ:BCDA) filed an 8-K announcing the grant of US Patent No. 12,311,127 titled "Radial and Trans-endocardial Delivery Catheter" by the United States Patent Office. The patent strengthens the company's intellectual property portfolio in medical device technology. The filing includes the announcement via press release and standard exhibits.
FAQ
What is the current stock price of Biocardia (BCDAW)?
